智通财经APP获悉，德琪医药-B(06996)再涨超11%，月内股价累涨超2.1倍。截至发稿，涨11.26%，报2.47港元，成交额1051.4万港元。
消息面上，德琪医药近日公布，公司计划加大投入，整合资源成立专门的AI部门。这一举措包括本地部署DeepSeek以加速具有空间位元阻遮蔽效应的T细胞衔接器（TCE）平台后续管线研发。据悉，公司早在2021年便以天使投资人身份投资杭州德睿智药AI药物发现平台，并借此战略性的切入了AI药物发现赛道。同时公司也已通过AI资料模型结合多组学分析，成功发现全新肝癌相关抗原(TAA)并将其开发为TCE候选药物进入临床前验证阶段。
此前，德琪医药宣布，希维奥®在台湾市场获批纳入全民健康保险，联合硼替佐米 (bortezomib) 和地塞米松 (dexamethasone) (XVd方案) 用于治疗接受过至少两种既往治疗的复发/难治性多发性骨髓瘤（R/R MM）成人患者。希维奥®将于3月1日起正式纳入台湾市场《全民健康保险用药品项表》。希维奥®是全球首个全新机制的口服选择性XPO1抑制剂，已在亚太市场的9个国家和地区获批用于治疗多项适应症，并在其中5个市场（中国大陆、台湾市场、澳大利亚、新加坡和韩国）实现医保收录。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.